Takahashi M, Ono K, Hamanaka D, Dodo Y, Hiraoka M, Abe M
Gan To Kagaku Ryoho. 1983 Mar;10(3):741-9.
The results of radiotherapy in the treatment of primary lung cancer is presented with reference to metastases in regional lymph nodes. The study involved 382 patients with histologically proven lung cancer of all cell types who, between 1945 and 1955, initially underwent definitive radiotherapy with TDF's of more than 70. The evaluable patients comprised 66 for N0, 177 for N1 and 139 for N2. Cumulative five-year survival rates for N0, N1 and N2 were 23.9%, 6.1% and 5.6%, respectively. Although surgical treatment before radiotherapy did not significantly improve a cumulative five-year survival rate for each N category, it kept patients alive longer for the median survival time (month). In 89 patients with involved mediastinal lymph nodes that specific sites were identified at the time of the surgical treatment (pN2), prolonged survival was obtained by radiotherapy if lymphatic spread was absent in the sites of #1, #2, #3, #5 and #6. If present, however, none of patients were alive at the post-treatment time of three years. As to 155 patients with stage III disease comprising T3 and/or N2, both cumulative five-year survival rate and median survival time showed better results in the group of N2 disease than those in T3.
本文参照区域淋巴结转移情况，介绍了原发性肺癌放射治疗的结果。该研究纳入了382例经组织学证实的各细胞类型肺癌患者，这些患者在1945年至1955年间最初接受了总剂量超过70的TDF根治性放疗。可评估的患者中，N0期有66例，N1期有177例，N2期有139例。N0、N1和N2期的累积五年生存率分别为23.9%、6.1%和5.6%。虽然放疗前的手术治疗并未显著提高各N分期的累积五年生存率，但在中位生存时间（月）方面，患者存活时间更长。在89例手术治疗时确定了纵隔淋巴结受累具体部位（pN2）的患者中，如果1、2、3、5和6区无淋巴转移，放射治疗可延长生存期。然而，如果存在淋巴转移，三年治疗后无一例患者存活。对于155例III期疾病（包括T3和/或N2）患者，N2疾病组的累积五年生存率和中位生存时间均优于T3疾病组。
